In the featured article from the February 2017 issue of The Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent—a PET radiotracer—is both safe and effective.
The new agent is a gallium-68 (Ga-68)-labeled peptide BBN-RGD agent that targets both gastrin-releasing peptide receptor (GRPR) and integrin ?v?3. Dual-receptor targeting provides advantages over single-receptor targeting by allowing tumor contrast when either or both receptor types are expressed, improving binding affinity and increasing the number of effective receptors.
Approximately one in seven men will be diagnosed with prostate cancer in his lifetime. In 2017, the American Cancer Society estimates that there will be more than 161,000 new prostate cancer cases in the United States and around 27,000 deaths from the disease. “Although treatable at the early stage, prostate cancer is prone to metastasis,” explain the team of authors, led by Xiaoyuan Chen, senior investigator, Laboratory of Molecular Imaging and Nanomedicine at the U.S. National Institute of Biomedical Imaging and Bioengineering. “An effective and specific imaging method of detecting both primary and metastatic lesions is thus of critical importance to manage patients with prostate cancer.”
This study included 13 patients with prostate cancer (four newly diagnosed and nine post-therapy) and five healthy volunteers. Ga-68-BBN-RGD PET/CT detected 20 bone lesions in seven patients either with primary prostate cancer or after radical prostatectomy. The patients with bone metastases did not necessarily have an elevated prostate specific antigen level. “This result is better than bone scanning with MDP,” Chen notes, referring to the most common radiotracer used today. “MDP bone scans are sensitive but lack specificity because localized skeletal accumulation of Tc-99m-MDP can also be observed in the case of trauma and infection.” No adverse side effects were found during the whole procedure and two-week follow-up, demonstrating the safety of Ga-68-BBN-RGD.
“Compounds capable of targeting more than one biomarker have the ability of binding to both early and metastatic stages of prostate cancer, creating the possibility for a more prompt and accurate diagnostic profile for both primary and the metastatic tumors,” explains Chen.
Looking ahead, Chen says, “Ga-68-BBN-RGD could play an additive role in staging and detecting prostate cancer and provide guidance for internal radiation therapy using the same peptide labeled with therapeutic radionuclides.” He points out that larger-scale clinical investigations are warranted.
[osd_subscribe categories=’prostate-cancer’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “PROSTATE CANCER”‘]
Receive an email update when we add a new PROSTATE CANCER article.
The Latest on: Prostate cancer
[google_news title=”” keyword=”prostate cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Prostate cancer
- SUO 2023: PSMA PET/CT-Detected Mesorectal Nodal Metastasis in Biochemically Recurrent Prostate Cancer Patientson November 29, 2023 at 6:31 am
Approximately 11% of prostate cancer patients with biochemical failure undergoing an 18 F-DCFPyL-PET/CT scan have mesorectal lymph node metastasis, with presence of pT3b disease associated with a 4.31 ...
- Raigmore Hospital launches packs to ease side effects of prostate cancer treatmenton November 29, 2023 at 12:17 am
Men under prostate cancer treatment at Raigmore Hospital can benefit from free goody packs aimed at easing some side effects.
- Clarity's theranostic prostate cancer trial progresses at the highest dose level cohorton November 28, 2023 at 9:58 pm
The aim of the trial is to determine the safety and efficacy of 67 Cu-SAR-bisPSMA for the treatment of prostate cancer. Cohort 3 of the trial has a 3+3 study design with the intent to gather and ...
- Revolutionising prostate cancer treatment: Government backs cutting-edge researchon November 28, 2023 at 8:53 pm
The government has given $5 million in funding to adapt a form of immunotherapy to treat prostate cancer, a leading cause of death in older men.
- Opposition criticizes B.C. government for plan to send cancer patients to U.S.on November 28, 2023 at 7:56 pm
The Opposition B.C. United Party criticized the ruling B.C. NDP Tuesday for its plan to send some cancer patients to the U.S. for radiation treatment.Under the plan, which was first announced in May, ...
- Flow of cancer patients to Bellingham clinics has not eased backlog at home, critics sayon November 28, 2023 at 5:49 pm
An average of 12 cancer patients a week have travelled to Bellingham in Washington State for radiation therapy, far short of the 50 patients a week the health ministry planned for to reduce the ...
- B.C. government-contracted cancer clinic must return millions to patientson November 28, 2023 at 4:00 pm
On May 15, NDP Minister of Health Adrian Dix announced that BC Cancer Agency had outsourced a limited number of breast and prostate radiation treatments to two clinics in Bellingham — PeaceHealth St.
- The Red Flag Pain Symptom That Can Be A Sign Of Prostate Canceron November 28, 2023 at 8:33 am
According to Cancer Research UK, prostate cancer doesn’t usually cause symptoms in the early stages and most prostate cancers start in the outer part of the prostate gland. This means that to cause ...
- The little-known 'pain' that could be a hidden sign of prostate canceron November 27, 2023 at 7:43 pm
A doctor is warning men about a little-known symptom of prostate cancer that they should get checked out. Getting any kind of pain and discomfort around the groin area can be worrying. And now a medic ...
via Bing News